0001493152-23-007004.txt : 20230308 0001493152-23-007004.hdr.sgml : 20230308 20230308162552 ACCESSION NUMBER: 0001493152-23-007004 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230308 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230308 DATE AS OF CHANGE: 20230308 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NEPHROS INC CENTRAL INDEX KEY: 0001196298 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 133971809 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-32288 FILM NUMBER: 23716445 BUSINESS ADDRESS: STREET 1: 380 LACKAWANNA PLACE CITY: SOUTH ORANGE STATE: NJ ZIP: 07079 BUSINESS PHONE: 201.343.5202 MAIL ADDRESS: STREET 1: 380 LACKAWANNA PLACE CITY: SOUTH ORANGE STATE: NJ ZIP: 07079 8-K 1 form8-k.htm
0001196298 false 0001196298 2023-03-08 2023-03-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): March 8, 2023

 

NEPHROS, INC.

(Exact name of Registrant as Specified in its Charter)

 

Delaware   001-32288   13-3971809
(State or other jurisdiction of  incorporation)  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

380 Lackawanna Place, South Orange, New Jersey 07079
(Address of principal executive offices, including ZIP code)

 

(201) 343-5202
(Registrant’s telephone number, including area code)

 

n/a
(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, $0.001 par value   NEPH   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 
 

 

Item 2.02.Results of Operations and Financial Condition.

 

On March 8, 2023, Nephros, Inc. (the “Company”) issued a press release in which it disclosed its fourth quarter and fiscal year 2022 financial results. A copy of this press release is furnished herewith as Exhibit 99.1.

 

Pursuant to the rules and regulations of the Securities and Exchange Commission, such exhibit and the information set forth therein and in this Item 2.02 have been furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to liability under that section nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing regardless of any general incorporation language.

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
99.1   Nephros, Inc. Press Release, dated March 8, 2023.
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Nephros, Inc.
   
Dated: March 8, 2023 By: /s/ Andrew Astor
    Andrew Astor
    Chief Executive Officer

 

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Nephros, Inc.
380 Lackawanna Place
South Orange NJ 07079
Call: 201 343 5202

nephros.com

 

Nephros Announces Fourth Quarter and Fiscal Year 2022 Financial Results

 

Full-Year Net Revenue of $10 Million and Fourth Quarter Net Revenue of $2.6 Million

 

SOUTH ORANGE, NJ, March 8, 2023 – Nephros, Inc. (Nasdaq: NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022.

 

Financial Highlights

 

Fourth Quarter Ended December 31, 2022 – Consolidated

 

●Net revenue from continuing operations was $2.6 million, compared to $2.7 million in the fourth quarter of 2021, down 6%
●Net loss from continuing operations was ($0.7 million), approximately equal to the same period in 2021
●Adjusted EBITDA from continuing operations was ($0.5 million), compared to ($0.1 million) in the
fourth quarter of 2021

 

Year-End 2022 – Consolidated

 

●Net revenue from continuing operations was $10.0 million, compared with $10.2 million in 2021, down 2%
●Net loss from continuing operations was ($4.3 million), compared with ($2.8 million) in 2021
●Adjusted EBITDA from continuing operations was ($2.4 million), compared with ($1.6 million) in 2021

 

“2022 was a year of refocusing and rebuilding for Nephros,” said Andy Astor, President and Chief Executive Officer. “After a challenging first half of the year, we established a target of cash flow breakeven (“CFBE”) by mid-year 2023, coupled with significant revenue growth by that same time. We have made good progress on both fronts.”

 

“In our efforts to achieve CFBE, we took multiple actions, including broad headcount and expense reductions, the disposition of our Pathogen Detection Systems (“PDS”) business segment, and two price increases during the year, which were intended to return us to target gross margins of 55-60%. I am pleased to report that our fourth-quarter gross margins were 59%. Additionally, our net cash usage for the first half of the year was $2.8 million, compared to $0.5 million in the second half of the year, an 80% improvement.”

 

Mr. Astor continued, “In an effort to set the company up for future revenue growth, we took several actions, including a restructuring of our sales organization, the doubling of our sales team, and the relaunch of our commercial filtration business, which included a rebrand of our commercial filter products from Aether to Nephros. Of further note, we established a strategic partnership with Donastar Enterprises, LLC as the exclusive master distributor of our commercial filters in the food & beverage and hospitality markets.”

 

Nephros anticipates further cost reductions in the second quarter of this year, due to the planned cessation of operations by our majority-owned subsidiary, Specialty Renal Products, Inc. (“SRP”). In February 2023, SRP management unsuccessfully concluded its efforts to identify a strategic partner to support a commercial launch of SRP’s second-generation HDF product. SRP’s capital resources are nearly exhausted and it has been unable to procure additional financing. Accordingly, the SRP board of directors recently resolved, subject to approval of SRP’s stockholders, to wind down SRP’s operations and liquidate its remaining assets. Nephros expects to re-evaluate opportunities for HDF in the future but has no immediate plans to do so.

 

1
 

 

Nephros, Inc.
380 Lackawanna Place
South Orange NJ 07079
Call: 201 343 5202

nephros.com

 

Financial Performance for the Fourth Quarter and Year Ended December 31, 2022

 

Net revenue from continuing operations for the year ended December 31, 2022 was $10 million, compared with $10.2 million in 2021, a decrease of 2%. Net revenues for the fourth quarter of 2022 were $2.6 million, compared with $2.7 million in the fourth quarter of 2021, a decrease of 6%.

 

Cost of goods sold for the year ended December 31, 2022 was $5.2 million, compared with $4.6 million in 2021, an increase of 14%. Cost of goods sold for the fourth quarter of 2022 was $1.0 million, compared with $1.2 million in the fourth quarter of 2021, a decrease of 16%.

 

Gross margins for the year ended December 31, 2022 were 47%, compared with 55% in 2021. Gross margins for the fourth quarter of 2022 were 59%, compared with 54% in the fourth quarter of 2021.

 

Selling, general and administrative expenses for the year ended December 31, 2022 were $7.6 million, compared with $7.2 million in 2021, an increase of 6%. Selling, general and administrative expenses for the fourth quarter of 2022 and 2021 were approximately $1.8 million.

 

Research and development expenses for the year ended December 31, 2022 were $1.3 million, compared with $1.5 million in 2021 a decrease of 16%. Research and development expenses for the fourth quarter of 2022 were $0.4 million, compared with $0.3 million in the fourth quarter of 2021, a decrease of 9%.

 

Depreciation and amortization expenses for the year ended December 31, 2022 were approximately $218,000, compared with approximately $192,000 in 2021, an increase of 14%. Depreciation and amortization expenses for the fourth quarter of 2022 were approximately $56,000, compared with approximately $42,000 in the fourth quarter of 2021, an increase of 33%.

 

Net loss from continuing operations for the year ended December 31, 2022 was ($4.3 million), compared with a net loss of ($2.8 million) in 2021, a 54% increase in loss. Net loss from continuing operations for the fourth quarter of 2022 and 2021 was approximately ($0.7 million) respectively.

 

Adjusted EBITDA loss from continuing operations for the year ended December 31, 2022 was ($2.4 million), compared with ($1.6 million) in 2021. Adjusted EBITDA loss from continuing operations for the fourth quarter 2022 was approximately ($0.5 million), compared with approximately ($0.1 million) in the fourth quarter of 2021.

 

As of December 31, 2022, Nephros had cash and cash equivalents of approximately $3.6 million.

 

2
 

 

Nephros, Inc.
380 Lackawanna Place
South Orange NJ 07079
Call: 201 343 5202

nephros.com

 

Consolidated Adjusted EBITDA Definition and Reconciliation to GAAP Financial Measures

 

Adjusted EBITDA loss from continuing operations is calculated by taking net loss from continuing operations calculated in accordance with generally accepted accounting principles (“GAAP”) and excluding all interest-related expenses and income, tax-related expenses and income, non-recurring expenses and income, and non-cash items, including depreciation, amortization and non-cash compensation. The following table presents a reconciliation of Adjusted EBITDA loss from continuing operations to net loss from continuing operations, the most directly comparable GAAP financial measure, for the fourth quarter of the 2022 and 2021 fiscal years:

 

2022  Three Month Period Ended   Annual 
Consolidated  3/31/2022   6/30/2022   9/30/2022   12/31/2022   Totals 
                     
Net (loss) income - from continuing operations   (1,561)   (747)   (1,250)   (719)   (4,277)
                          
Adjustments:                         
Depreciation of property and equipment   8    20    12    12    52 
Amortization of other assets   47    41    44    44    176 
Interest expense   7    6    4    3    20 
Interest income   (2)   (1)   (4)   (7)   (14)
Non-cash stock-based compensation   254    258    225    207    944 
Other non-cash items   49    21    665    -    735 
                          
Adjusted EBITDA   (1,198)   (402)   (304)   (460)   (2,364)

 

2021  Three Month Period Ended   Annual 
Consolidated  3/31/2021   6/30/2021   9/30/2021   12/31/2021   Totals 
                     
Net (loss) income - from continuing operations   (317)   (940)   (802)   (725)   (2,784)
                          
Adjustments:                         
Depreciation of property and equipment   7    7    7    16    38 
Amortization of other assets   46    48    46    74    214 
Interest expense   13    11    10    7    41 
Interest income   (3)   (3)   (2)   (2)   (10)
PPP Loan Forgiveness   (482)   -    -    -    (482)
Non-cash stock-based compensation   267    270    257    422    1,216 
Other non-cash items   5    24    90    97    216 
                          
Adjusted EBITDA   (464)   (583)   (394)   (111)   (1,552)

 

3
 

 

Nephros, Inc.
380 Lackawanna Place
South Orange NJ 07079
Call: 201 343 5202

nephros.com

 

Nephros believes that Adjusted EBITDA loss from continuing operations provides useful information to management and investors regarding certain financial and business trends relating to Nephros’ financial condition and results of operations. Management does not consider Adjusted EBITDA loss from continuing operations in isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of Adjusted EBITDA loss from continuing operations is that it excludes significant expenses and income that are required by GAAP to be recognized in Nephros’ consolidated financial statements. In addition, Adjusted EBITDA loss from continuing operations is subject to inherent limitations as it reflects the exercise of judgments by management about which expenses and income are excluded or included in determining Adjusted EBITDA loss from continuing operations. In order to compensate for these limitations, management presents Adjusted EBITDA loss from continuing operations in connection with net loss from continuing operations, the most directly comparable GAAP financial measure. Nephros urges investors to review the reconciliation of Adjusted EBITDA loss from continuing operations to net loss from continuing operations and not to rely on any single financial measure to evaluate the business.

 

Conference Call Today at 4:30pm Eastern Time

 

Nephros will host a conference call today at 4:30pm ET, during which management will discuss Nephros’ financial results and provide a general business overview.

 

Participants may dial into the call as follows:

Domestic access: 1 (844) 808-7106

International access: 1 (412) 317-5285

 

Upon joining, please ask to be joined into the Nephros conference call.

 

An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page.

 

Alternatively, a replay of the call may be accessed until March 15th, 2023 at 1 (877) 344-7529 or 1 (412) 317-0088 for international callers and entering replay access code: 9907282.

 

About Nephros

 

Nephros is committed to improving the human relationship with water through leading, accessible technology. We provide innovative water filtration products and services, along with water-quality education, as part of an integrated approach to water safety. Nephros goods serve the needs of customers within the healthcare and commercial markets, offering both proactive and emergency solutions for water management.

 

For more information about Nephros, please visit www.nephros.com.

 

4
 

 

Nephros, Inc.
380 Lackawanna Place
South Orange NJ 07079
Call: 201 343 5202

nephros.com

 

Forward-Looking Statements

 

This release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding Nephros’ expected revenue and cash flows for the quarter and year ended December 31, 2022, expected future revenue growth and the timing of such growth, expectations regarding achieving cash flow breakeven and the timing thereof, and other statements that are not historical facts, including statements that may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to certain factors, including the impact of the ongoing COVID-19 pandemic, changes in business, Nephros’ ability to further develop its sales organization and realize increased revenues, inflationary factors and other economic and competitive conditions, the availability of capital when needed, dependence on third-party manufacturers and researchers, and regulatory reforms. These and other risks and uncertainties are detailed in Nephros’ reports filed with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2022, which is expected to be filed on or before March 31, 2023. Nephros does not undertake any responsibility to update the forward-looking statements in this release.

 

Investor Relations Contacts:

 

Kirin Smith, President

PCG Advisory, Inc.

(646) 823-8656

ksmith@pcgadvisory.com

 

Andy Astor, CEO

Nephros, Inc.

(201) 343-5202 x120

andy.astor@nephros.com

 

5
 

 

NEPHROS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share amounts)

(Unaudited)

 

   December 31, 2022   December 31, 2021 
ASSETS          
Current assets:          
Cash and cash equivalents  $3,634   $6,973 
Accounts receivable, net   1,286    1,641 
Inventory   3,153    4,462 
Prepaid expenses and other current assets   188    207 
Current assets held for sale   -    351 
Total current assets   8,261    13,634 
Property and equipment, net   116    72 
Lease right-use-of assets   984    614 
Intangible assets, net   423    465 
Goodwill   759    759 
License and supply agreement, net   402    536 
Other assets   54    84 
Non-current assets associated with discontinued operations   -    1,486 
TOTAL ASSETS  $10,999   $17,650 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current liabilities:          
Current portion of secured note payable   71    248 
Accounts payable   740    1,334 
Accrued expenses   285    444 
Current portion of lease liabilities   316    313 
Current liabilities associated with assets held-for-sale   -    51 
Total current liabilities   1,412    2,390 
Secured note payable, net of current portion   -    95 
Equipment financing, net of current portion   1    4 
Lease liabilities, net of current portion   705    340 
Non-current liabilities associated with discontinued operations   -    72 
TOTAL LIABILITIES   2,118    2,901 
           
COMMITMENTS AND CONTINGENCIES          
           
STOCKHOLDERS’ EQUITY:          
Preferred stock, $.001 par value; 5,000,000 shares authorized at December 31, 2022 and 2021; no shares issued and outstanding at December 31, 2022 and 2021   -    - 
Common stock, $.001 par value; 40,000,000 shares authorized at December 31, 2022 and 2021; 10,297,429 and 10,258,444 shares issued and outstanding at December 31, 2022 and 2021, respectively   10    10 
Additional paid-in capital   148,413    147,346 
Accumulated other comprehensive income   -    64 
Accumulated deficit   (142,831)   (135,725)
Subtotal   5,592    11,695 
Noncontrolling interest   3,289    3,054 
TOTAL STOCKHOLDERS’ EQUITY   8,881    14,749 
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY  $10,999   $17,650 

 

6
 

 

NEPHROS, INC. AND SUBSIDIARIES

 CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share amounts)

(Unaudited)

 

   Twelve Months Ended December 31, 
   2022   2021 
Net revenue:          
Product revenues  $9,929   $10,065 
Royalty and other revenues   46    152 
Total net revenues   9,975    10,217 
Cost of goods sold   5,244    4,584 
Gross margin   4,731    5,633 
           
Operating expenses:          
Research and development   1,255    1,498 
Depreciation and amortization   218    192 
Selling, general and administrative   7,593    7,195 
Total operating expenses   9,066    8,885 
Loss from continuing operations   (4,335)   (3,252)
Other (expense) income:          
Interest expense   (20)   (41)
Interest income   14    10 
Extinguishment of PPP Loan   -    482 
Other income, net   64    17 
Total other income:   58    468 
Loss from continuing operations   (4,277)   (2,784)
Net loss from discontinued operations   (2,829)   (1,083)
Net loss   (7,106)   (3,867)
Less: undeclared deemed dividend attributable to continuing noncontrolling interest   (276)   (240)
Net loss attributable to Nephros Inc. shareholders   (7,382)   (4,107)
           
Net loss per common share , basic and diluted from continuing operations   (0.42)   (0.28)
Net loss per common share, basic and diluted, from discontinued operations   (0.28)   (0.11)
Net loss per common share, basic and diluted  $(0.70)  $(0.39)
           
Net loss per common share, basic and diluted, attributable to continuing noncontrolling interest   (0.03)   (0.02)
           
Net loss per common share, basic and diluted attributable to Nephros Inc. shareholders  $(0.73)  $(0.41)
           
Weighted average common shares outstanding, basic and diluted   10,297,134    10,017,830 
           
Comprehensive loss:          
Net loss  $(7,106)  $(3,867)
Other comprehensive income, foreign currency translation adjustments, net of tax   (14)   (10)
Comprehensive loss   (7,120)   (3,877)
Comprehensive loss attributable to continuing noncontrolling interest   (276)   (240)
Comprehensive loss attributable to Nephros, Inc. shareholders  $(7,396)  $(4,117)

 

7

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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neph-20230308.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 neph-20230308_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 neph-20230308_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Mar. 08, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Mar. 08, 2023
Entity File Number 001-32288
Entity Registrant Name NEPHROS, INC.
Entity Central Index Key 0001196298
Entity Tax Identification Number 13-3971809
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 380 Lackawanna Place
Entity Address, City or Town South Orange
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07079
City Area Code (201)
Local Phone Number 343-5202
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, $0.001 par value
Trading Symbol NEPH
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001196298 2023-03-08 2023-03-08 iso4217:USD shares iso4217:USD shares 0001196298 false 8-K 2023-03-08 NEPHROS, INC. DE 001-32288 13-3971809 380 Lackawanna Place South Orange NJ 07079 (201) 343-5202 false false false false Common stock, $0.001 par value NEPH NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://nephros.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm neph-20230308.xsd neph-20230308_lab.xml neph-20230308_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "neph-20230308_lab.xml" ] }, "presentationLink": { "local": [ "neph-20230308_pre.xml" ] }, "schema": { "local": [ "neph-20230308.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "NEPH", "nsuri": "http://nephros.com/20230308", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-03-08to2023-03-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://nephros.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "From2023-03-08to2023-03-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://nephros.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001493152-23-007004-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-007004-xbrl.zip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end